Yüklüyor......
Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
Doxorubicin is a first-line therapy for patients with unresectable advanced soft tissue sarcoma (STS). However, because of cardiotoxicities, it is not used for patients with cardiac problems. Eribulin has exhibited efficacy for advanced STS in second- or later-line treatments. In the present study,...
Kaydedildi:
| Yayımlandı: | Sci Rep |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7708971/ https://ncbi.nlm.nih.gov/pubmed/33262403 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-77898-y |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|